Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Blood (2019) 134 (Supplement_1): 5276.

https://doi.org/10.1182/blood-2019-130484

Published: 2019

Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Blood (2018) 132 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2018-99-116610

Published: 2018

Journal Articles

Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Tomasz Szczepaniak, MD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Joanna Czerwinska-Rybak, MSc, Adam Nowicki, MD PhD, Monika Joks, MD PhD, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2016) 128 (22): 2092.

https://doi.org/10.1182/blood.V128.22.2092.2092

Published: 2016

Journal Articles

The Role of the Slit-Robo Family in Adult Patients with Acute Myeloid Leukemia

Aleksandra Golos, MD PhD, Dorota Jesionek-Kupnicka, MD PhD, Tadeusz Robak, MD PhD, Ewa Wawrzyniak, PhD, Lidia Anna Gil, MD PhD, Mieczyslaw Komarnicki, MD PhD, Anna Wache, MD, Agnieszka Wierzbowska, MD PhD

Blood (2015) 126 (23): 3816.

https://doi.org/10.1182/blood.V126.23.3816.3816

Published: 2015

Journal Articles

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Adam Nowicki, MD, Joanna Czerwinska-Rybak, MSc, Monika Joks, MD PhD, Tomasz Szczepaniak, MD PhD, Bochenek Maciej, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2015) 126 (23): 2986.

https://doi.org/10.1182/blood.V126.23.2986.2986

Published: 2015

Journal Articles

Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation

Blood (2014) 124 (21): 2564.

https://doi.org/10.1182/blood.V124.21.2564.2564

Published: 2014

Journal Articles

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Anna Czyz, Monika Joks, Joanna E Drozd-Sokolowska, Wanda Knopinska-Posluszny, Magdalena Zawartko, Ewa Mizera-Nyczak, Dominik Dytfeld, Barbara Zdziarska, Wiktor-Wieslaw Jedrzejczak, Mieczyslaw Komarnicki

Blood (2014) 124 (21): 5413.

https://doi.org/10.1182/blood.V124.21.5413.5413

Published: 2014

Journal Articles

Gene Polymorphism Profile May Predict Late Complications In Patients Undergoing Allogeneic Stem Cell Transplantation

Lidia Gil, MD PhD, Marzena Wojtaszewska, Anna Mol, Krzysztof Lewandowski, MD PhD, Jan Styczynski, MD, PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2013) 122 (21): 3321.

https://doi.org/10.1182/blood.V122.21.3321.3321

Published: 2013

Journal Articles

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Lidia Gil, MD PhD, Jan Styczynski, MD, PhD, Agnieszka Piekarska, MD PhD, Beata Jakubas, MD PhD, Katarzyna Drabko, MD PhD, Tomasz Wrobel, prof., Anna Czyz, MD PhD, Anna Lojko-Dankowska, MD PhD, Dominik Dytfeld, MD PhD, Adam Nowicki, MD, Patrycja Mensah-Glanowska, MD PhD, Wanda Knopinska-Posluszny, MD, PhD, Maria Bieniaszewska, MD PhD, Mariusz Wysocki, MD, PhD, Andrzej Hellmann, MD, PhD, Aleksander Skotnicki, Jerzy Kowalczyk, Kazimierz Kuliczkowski, MD PhD, prof., Mieczyslaw Komarnicki, MD PhD

Blood (2011) 118 (21): 3109.

https://doi.org/10.1182/blood.V118.21.3109.3109

Published: 2011

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Blood (2010) 116 (21): 2138.

https://doi.org/10.1182/blood.V116.21.2138.2138

Published: 2010

Journal Articles

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Anna Czyz, Adam Nowicki, Lidia Gil, Dominik Dytfeld, Anna Lojko-Dankowska, Jan Styczynski, PhD, Mieczyslaw Komarnicki

Blood (2010) 116 (21): 2822.

https://doi.org/10.1182/blood.V116.21.2822.2822

Published: 2010

Journal Articles

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Alain Kentos, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Dixie-Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel

Blood (2010) 116 (19): 3743–3750.

https://doi.org/10.1182/blood-2010-03-275800

Published: 2010

Includes: Supplemental data

Journal Articles

Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged < 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.

Blood (2009) 114 (22): 2055.

https://doi.org/10.1182/blood.V114.22.2055.2055

Published: 2009

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.

Anna Czyz, Anna Lojko, Lidia Gil, Dominik Dytfeld, Danuta Drozdowska, Adam Nowicki, Maria Kozlowska, Krzysztof Sawinski, Jan Styczynski, Mieczyslaw Komarnicki

Blood (2009) 114 (22): 3406.

https://doi.org/10.1182/blood.V114.22.3406.3406

Published: 2009

Journal Articles

Bortezomib Has No. Ex Vivo Activity in Chronic Myeloid Leukemia: Individual Tumor Response Testing Comparative Study in Pediatric and Adult Acute and Chronic Leukemia.

Krzysztof Czyzewski, Lidia Gil, Beata Kolodziej, Beata Rafinska, Krzysztof Lewandowski, Michal Gniot, Maria Lewandowska, Mieczyslaw Komarnicki, Mariusz Wysocki, Jan Styczynski

Blood (2009) 114 (22): 4257.

https://doi.org/10.1182/blood.V114.22.4257.4257

Published: 2009

Journal Articles

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul Richardson, Rudolf Schlag, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Rik Schots, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F San Miguel

Blood (2008) 112 (11): 2778.

https://doi.org/10.1182/blood.V112.11.2778.2778

Published: 2008

Journal Articles

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Blood (2008) 112 (11): 4301.

https://doi.org/10.1182/blood.V112.11.4301.4301

Published: 2008

Journal Articles

Comparative Analysis of Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation in Treatment of Patients with Chronic Myeloid Leukemia.

Jan Styczynski, PhD, Lidia Gil, PhD, Jan Maciej Zaucha, PhD, Anna Czyz, PhD, Maria Bieniaszewska, PhD, Mariusz Wysocki, PhD, Andrzej Hellmann, PhD, Mieczyslaw Komarnicki, PhD

Blood (2006) 108 (11): 5385.

https://doi.org/10.1182/blood.V108.11.5385.5385

Published: 2006

Journal Articles

Bone Marrow Stem Cells Infusion in Treatment of Patients with Acute Myocardial Infarction.

Lidia Gil, PhD, Anna Czyz, PhD, Krzysztof Sawinski, PhD, Maria Kozlowska-Skrzypczak, PhD, Mieczyslaw Komarnicki, PhD, Stefan Grajek, PhD, Maciej Lesiak, PhD, Malgorzata Popiel, PhD, Piotr Breborowicz, PhD, Andrzej Cieslinski, PhD, Rafal Czepczynski, PhD, Jerzy Sowinski, PhD, Jan Styczynski, PhD

Blood (2006) 108 (11): 1682.

https://doi.org/10.1182/blood.V108.11.1682.1682

Published: 2006

Journal Articles

Comparative Analysis of Ablative and Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation in Treatment of Adult Patients with Chronic Myeloid Leukemia.

Lidia Gil, Jan M. Zaucha, Jan Styczynski, Anna Czyz, Andrzej Hellmann, Mieczyslaw Komarnicki

Blood (2005) 106 (11): 5414.

https://doi.org/10.1182/blood.V106.11.5414.5414

Published: 2005

NARROW

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy

The Role of the Slit-Robo Family in Adult Patients with Acute Myeloid Leukemia

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Gene Polymorphism Profile May Predict Late Complications In Patients Undergoing Allogeneic Stem Cell Transplantation

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Gemcitabine-Based Salvage Chemotherapy as a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for the Patients with Relapse of Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation.

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Autologous Hematopoietic Stem Cell Transplantation Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's Lymphoma – Prognostic Factors and Long-Term Outcomes.

Bortezomib Has No. Ex Vivo Activity in Chronic Myeloid Leukemia: Individual Tumor Response Testing Comparative Study in Pediatric and Adult Acute and Chronic Leukemia.

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Comparative Analysis of Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation in Treatment of Patients with Chronic Myeloid Leukemia.

Bone Marrow Stem Cells Infusion in Treatment of Patients with Acute Myocardial Infarction.

Comparative Analysis of Ablative and Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation in Treatment of Adult Patients with Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only